Achillion Pharmaceuticals (NASDAQ:ACHN) has tumbled 10.79% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.19% in the last four weeks. The stocks have underperformed the S&P 500 by 9.72% during the past week but Achillion Pharmaceuticals (NASDAQ:ACHN) it has outperformed the index in 4 weeks by 0.26%.
Achillion Pharmaceuticals (NASDAQ:ACHN): The stock opened at $9.10 on Friday but the bulls could not build on the opening and the stock topped out at $9.17 for the day. The stock traded down to $8.50 during the day, due to lack of any buying support eventually closed down at $8.52 with a loss of -6.37% for the day. The stock had closed at $9.10 on the previous day. The total traded volume was 3,384,723 shares.
The company shares have dropped -5.86% from its 1 Year high price. On Dec 30, 2015, the shares registered one year high at $10.95 and the one year low was seen on Feb 12, 2016. The 50-Day Moving Average price is $8.77 and the 200 Day Moving Average price is recorded at $8.26.
On the companys insider trading activities, The Securities and Exchange Commission has divulged that Fenton Mary Kay, officer (Chief Financial Officer) of Achillion Pharmaceuticals Inc, had unloaded 43,500 shares at an average price of $10.08 in a transaction dated on December 28, 2015. The total value of the transaction was worth $438,480.
Many analysts have stated their opinion on the company shares. Leerink Swann maintains their rating on the shares of Achillion Pharmaceuticals (NASDAQ:ACHN). The current rating of the shares is Market Perform. Equity Analysts at the Firm raises the price target to $9 per share from $7 per share. The rating by the firm was issued on May 4, 2016. Currently the company Insiders own 6.52% of Achillion Pharmaceuticals shares according to the proxy statements. Institutional Investors own 81.98% of Achillion Pharmaceuticals shares.
Achillion Pharmaceuticals, Inc. is a biopharmaceutical company. The Companys primary business is to discover, develop and commercialize small molecule therapeutics for the treatment of infectious diseases and immune system disorders. The Company is focused on developing short-duration combination therapies for the treatment of chronic hepatitis C virus, or HCV, infection that are once-daily and ribavirin-free. The Company is advancing several combination regimens, including ACH-3102, a NS5A inhibitor, which is under Phase II clinical development, ACH-3422, a NS5B nucleotide polymerase inhibitor, which is under Phase I clinical development, and Sovaprevir, a NS3 protease inhibitor, which is under Phase II clinical development.